Planning advanced therapy trials for Huntington's Disease: ethical considerations.

Authors

Towns Cindy, Ballantyne Angela, Konstatinova Pavlina, Drew Cheney, Rosser Anne

Published in

Molecular therapy : the journal of the American Society of Gene Therapy. Sep 28, 2026. Epub Sep 28, 2026.

Abstract

Huntington's Disease (HD) is a relentlessly progressive genetic disorder characterised by cognitive, behavioural and physical impairments. The lack of effective treatments, early onset of symptoms and high rates of suicide reflect a disease of significant human suffering. The ethical imperative to pursue disease modifying treatments with gene and stem cell therapies - collectively referred to as advanced therapeutic medicinal products (ATMPs) - is therefore sound. Recent gene therapy trials have generated international attention and widespread hope in the HD community, however gene and stem cell therapies are fraught with ethical challenges and complexity. Genetic discrimination, trial design challenges (especially the use of surgical placebos) and the risk for therapeutic misconception need careful consideration whilst broader concerns relating to justice and equity must be recognised by researchers and funders alike. This paper will provide those involved in gene therapy trials and other advanced therapy research a comprehensive overview of the ethical issues.

PMID:
42802556
Bibliographic data and abstract were imported from PubMed on 28 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.